Adma Biologics Inc

ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The company manufactures and markets three FDA-approved plasma-derived biologics: ASCENIV (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ASCENIV is manufactured using ADMA's patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma with RSV plasma from donors tested using a proprietary microneutralization assay. ADMA is also advancing SG-001, a pre-clinical investigative hyperimmune globulin targeting S. pneumoniae, leveraging its existing platform and commercial infrastructure toward an estimated $300-$500 million market opportunity. The company manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and operates FDA-approved source plasma collection centers through its ADMA BioCenters subsidiary. Updated Aug 5, 2026